Kairos Pharma Ltd Dossier
Qualitative Analysis
Business overview
Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapeutics designed to overcome drug resistance and immune suppression in cancer. Spun out of Cedars-Sinai Medical Center, the company's pipeline includes antibodies and small molecules targeting prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead therapeutic candidate is ENV-105 (carotuximab), a first-in-class CD105-targeting antibody designed to reverse resistance to standard hormone therapies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the development of therapeutics designed to overcome cancer drug resistance and immune suppression, specifically focusing on CD105-targeting (ENV-105) and newly acquired EGFR/c-MET pathways.
Expected impact: Aims to restore tumor sensitivity to standard-of-care therapies, improving progression-free survival in hard-to-treat cancers like mCRPC and NSCLC.
Actively pursuing strategic collaborations with major pharmaceutical companies to test the synergy of lead candidate ENV-105 in combination with established blockbuster oncology drugs.
Expected impact: Leverages combination therapies to revitalize existing blockbuster drugs, creating a commercial pathway and co-development opportunities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of exclusive worldwide rights to CL-273 (a pre-IND, wild-type-sparing pan-EGFR inhibitor) and CL-741 (a Phase 1-ready c-MET kinase inhibitor) to target the multi-billion dollar EGFR-mutant and c-MET-driven lung cancer markets.
Financial impact: Celyn to receive 16.5% fully diluted capital stock of Kairos at closing, a single regulatory milestone of $15 million (payable in cash/shares) upon US FDA NDA submission, and a 2% royalty on US net revenues.
Strategic Partnerships
Provides Kairos with the essential clinical infrastructure, operational expertise, and patient consortia on the West Coast to rapidly initiate and execute Phase 1 and Phase 2 clinical trials.
Terms: Not explicitly disclosed